Tscan Therapeutics Inc
(TCRX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -22,563 | -66,221 | -47,498 | -31,253 | -16,156 |
| Depreciation Amortization | 1,499 | 5,137 | 3,653 | 2,402 | 1,195 |
| Accounts payable and accrued liabilities | 495 | 528 | 114 | 1,232 | 824 |
| Other Working Capital | -3,884 | -10,230 | -9,946 | -6,648 | -6,147 |
| Other Operating Activity | 866 | 4,283 | 3,184 | 776 | 160 |
| Operating Cash Flow | $-23,587 | $-66,503 | $-50,493 | $-33,491 | $-20,124 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -838 | -4,225 | -2,848 | -2,424 | -531 |
| Investing Cash Flow | $-838 | $-4,225 | $-2,848 | $-2,424 | $-531 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 29,354 | 29,354 | N/A | N/A |
| Common Stock Issued | N/A | 326 | 124 | 119 | 88 |
| Other Financing Activity | 0 | -324 | -230 | 0 | 0 |
| Financing Cash Flow | $N/A | $29,356 | $29,248 | $119 | $88 |
| Beginning Cash Position | 125,064 | 166,436 | 166,436 | 166,436 | 166,436 |
| End Cash Position | 100,639 | 125,064 | 142,343 | 130,640 | 145,869 |
| Net Cash Flow | $-24,425 | $-41,372 | $-24,093 | $-35,796 | $-20,567 |
| Free Cash Flow | |||||
| Operating Cash Flow | -23,587 | -66,503 | -50,493 | -33,491 | -20,124 |
| Capital Expenditure | -838 | -4,225 | -2,848 | -2,424 | -531 |
| Free Cash Flow | -24,425 | -70,728 | -53,341 | -35,915 | -20,655 |